Company Filing History:
Years Active: 2024
Title: The Innovative Contributions of Sabrina Frey in Microfluidics
Introduction
Sabrina Frey, an accomplished inventor based in Bern, Switzerland, has made significant strides in the field of biomedical engineering. Her innovative work has led to the development of a groundbreaking patent designed to enhance the understanding and treatment of microvascular obstruction (MVO) in patients.
Latest Patents
Frey holds a patent for her invention titled "Microfluidic Coronary Circulatory Model". This patent encompasses systems, methods, and apparatuses that are specifically configured to model MVO in patients. The multi-scale model aims to simulate the myocardial microcirculation of coronary vessels by incorporating collaterals that provide alternative pathways, potentially bypassing MVO. It also models coronary artery compliance to facilitate spatially resolved fluid transport through coronary vessels. By increasing flow resistance or completely blocking modeled coronary vessels, this innovative model simulates MVO effectively. Furthermore, it mimics fluid transport behavior during diagnostics or treatment, which is instrumental in designing and optimizing therapy protocols for MVO.
Career Highlights
Sabrina Frey has channeled her expertise into her role at Corflow Therapeutics AG, where she has contributed to advancing research in coronary circulatory systems. Her work reflects a commitment to innovation and improving patient outcomes through advanced biomedical solutions.
Collaborations
In her professional journey, Frey has collaborated with esteemed colleagues such as Andre Bernard and Peter Heeb. This teamwork has fostered a rich environment for innovation and has propelled many projects forward in the realm of microfluidics and cardiovascular research.
Conclusion
Sabrina Frey's contributions to the field of biomedical engineering, particularly through her patented microfluidic model, exemplify the impact of innovation in healthcare. Her work not only furthers understanding of coronary circulatory systems but also paves the way for future advancements in the treatment and management of microvascular conditions.